Novavax in the spotlight (part VI)
Delays, boosters, and more...
Novavax (NVAX) had their Q2 business update call last week after market. The company announced yet another delay in the US submission, while the rest of the world’s regulatory submissions were on schedule for Q3 submissions. The stock went down 10% in premarket trading the morning following that news.
Regulatory Submission Updates
Novavax announced that …